[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634344":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":16,"studyPopulation":16,"armGroups":23,"interventions":35,"overallOfficials":16,"centralContacts":45,"locations":51,"responsibleParty":62,"collaborators":16,"id":64,"slug":16,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":16,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":16,"enrollmentInfo":73,"targetDuration":16,"studyType":76,"phases":77,"briefSummary":67,"conditions":79,"keywords":16,"overallStatus":81,"whyStopped":16,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"Maximum concentration of drug in plasma (Cmax)","Cmax of AD-123","pre-dose to 72 hours",{"measure":14,"description":15,"timeFrame":12},"Area under the plasma concentration-time curve during dosing interval (AUCt)","AUCt of AD-123",null,{"allocation":18,"interventionModel":19,"interventionModelDescription":16,"primaryPurpose":20,"observationalModel":16,"timePerspective":16,"maskingInfo":21},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":22,"maskingDescription":16,"whoMasked":16},"NONE",[24,31],{"label":25,"type":26,"description":27,"interventionNames":28},"Sequence A (RT)","EXPERIMENTAL","Period 1 : Reference Drug(AD-1231 and AD-1232), Period 2 : Test Drug(AD-123)",[29,30],"Drug: AD-123","Drug: AD-1231 and AD-1232",{"label":32,"type":26,"description":33,"interventionNames":34},"Sequence B (TR)","Period 1 : Test Drug(AD-123), Period 2 : Reference Drug(AD-1231 and AD-1232)",[29,30],[36,41],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":16},"DRUG","AD-123","AD-123 Oral Tablet",[25,32],{"type":37,"name":42,"description":43,"armGroupLabels":44,"otherNames":16},"AD-1231 and AD-1232","AD-1231 Oral Tablet + AD-1232 Oral Tablet",[25,32],[46],{"name":47,"role":48,"phone":49,"phoneExt":16,"email":50},"Dasom Kim","CONTACT","+82-31-891-5572","dskim@addpharma.co.kr",[52],{"facility":53,"status":16,"city":54,"state":16,"zip":16,"country":55,"countryCode":16,"cosmosGeoPoint":56,"geoPoint":61,"contacts":16},"H Plus Yangji Hospita","Seoul","South Korea",{"type":57,"coordinates":58},"Point",[59,60],126.9784,37.566,{"lat":60,"lon":59},{"type":63,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100634344",false,"NCT07538466","A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232 in Healthy Adult Volunteers Under Fasting Conditions","Inclusion Criteria:\n\n* Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"ALL","19 Years",{"count":74,"type":75},50,"ESTIMATED","INTERVENTIONAL",[78],"PHASE1",[80],"Diabetes Mellitus","NOT_YET_RECRUITING","2026-04-12",{"date":84,"type":85},"2026-04-20","ACTUAL",{"date":87,"type":75},"2026-04",{"date":89,"type":75},"2026-05",{"name":5,"class":6},1]